| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 3 data readout example | VRDN-003 (subcutaneous anti-IGF-1R antibody) Chronic thyroid eye disease (TED) | Phase 3 | — | Biologics | Ophthalmologic System | ||
Phase 3 data readout example | VRDN-003 (subcutaneous anti-IGF-1R antibody) Chronic thyroid eye disease (TED) | Phase 3 | — | Biologics | Ophthalmologic System | ||
Phase 3 data readout example | VRDN-003 (subcutaneous anti-IGF-1R antibody) Chronic thyroid eye disease (TED) | Phase 3 | — | Biologics | Ophthalmologic System |
Recent Updates
Recently added Catalysts
Viridian Therapeutics, Inc.$17.9
+0.51 (+2.93%)
C 43Pipeline Score Overvalued Pharma · Commercial
Market Cap
1.78 B
EPS
-3.76
P/E Ratio
-
Value Trade
27.38 M
SEC Financials
Q1 2026Dilution Risk
25%Revenue
141.00 K
R&D Expenses
77.63 M
Operating CF
-119.65 M
Total Assets
789.02 M
Total Liabilities
153.01 M
Equity
636.01 M
D/E Ratio
12,345
-0.12 %
Week
19.64 %
1 Month
-38.84 %
3 Month
-41.18 %
6 Month
-3.9 %
5 Year
-99.17 %
All Time
Cash Data
Cash Position
762.20 M
Monthly Burn
39.88 M
Runway
17.4 mo
Burn Trend
SEC Filing
May 5, 2026
Overview
Volume
5.69 M
52 Week Range
13.18 - 34.29
% held by Insiders
7.2 %
% held by Institutions
101.12 %
Enterprise Value
1.20 B
Total Shares
95.40 M
Short %
14.65 %
Float Shares
86.34 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
C43
Pipeline Score $328M
Pipeline ValueOvervalued
Valuation Signal3
Drugs Scored0.2x
rNPV / MCap Top 64%
Micro Cap (rank 327 of 905)
Percentile RankViridian Therapeutics, Inc. carries a moderate pipeline score (43/100), with $820M risk-adjusted pipeline value, led by Veligrotug in Thyroid Eye Disease (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Veligrotug Small molecule | Thyroid Eye Disease | Phase 3 | NCT06021054 | 90% | $446M | COMPLETED | 331 | - | - | Jul 25, 2025 | - | Oct 23, 2025 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
VRDN-001 | thyroid eye disease | Phase 3 | 2025-07-04 | |||
VRDN-001 | thyroid eye disease | Phase 3 | 2025-07-04 | |||
VRDN-001 | thyroid eye disease | Phase 3 | 2025-07-04 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in VRDN
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
VRDN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
VRDN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
VRDN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
VRDN Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
VRDN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
VRDNViridian Therapeutics to Participate in Upcoming June Investor Conferences
Viridian Therapeutics is set to participate in several investor conferences scheduled for June. The company aims to engage with investors and provide updates on its ongoing projects and developments. This participation reflects Viridian's commitment to maintaining investor relations and transparency.
Read more →VRDNViridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million
Viridian Therapeutics has announced the pricing of its upsized concurrent public offerings, which include 1.75% convertible senior notes due in 2032 and common stock. The aggregate gross proceeds from these offerings are expected to be $350 million. This move is part of the company's strategy to raise capital.
Read more →VRDNViridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock
Viridian Therapeutics has announced proposed concurrent public offerings of convertible senior notes due 2032, common stock, and Series B non-voting convertible preferred stock. This move is part of their strategy to raise capital. Further details regarding the offerings have not been disclosed.
Read more →VRDNViridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease
Viridian Therapeutics has reported positive topline results from its Phase 3 REVEAL-2 clinical trial for Elegrobart, aimed at treating chronic thyroid eye disease. This outcome suggests a promising advancement in therapeutic options for patients. The results may enhance the company's position in the biopharma market.
Read more →VRDNViridian Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Progress
Viridian Therapeutics has reported its financial results for the first quarter of 2026, highlighting recent advancements. However, specific details about the financial performance and progress were not disclosed in the article. The report appears to focus on the company's ongoing developments in the biopharma sector.
Read more →VRDNViridian Therapeutics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Johnson Fistel, PLLP is investigating potential claims on behalf of Viridian Therapeutics, Inc. investors who suffered losses. The investigation follows Viridian's recent announcement that its REVEAL-1 Phase 3 trial met its primary endpoint with statistically significant results. However, concerns have emerged regarding the company's compliance with federal securities laws, prompting the investigation. Interested investors are encouraged to reach out to Johnson Fistel for more information on potential recovery options.
Read more →VRDNViridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease
Viridian Therapeutics has announced positive topline results from its Phase 3 REVEAL-1 clinical trial for Elegrobart, aimed at treating active thyroid eye disease. This development suggests a significant step forward in the treatment options available for patients suffering from this condition. The results may pave the way for further advancements in therapeutic approaches.
Read more →VRDNViridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results
Viridian Therapeutics reported significant progress in its pipeline, including a Priority Review for the BLA filing of veligrotug, with a PDUFA date of June 30, 2026. The company is also preparing to release pivotal data for elegrobart next month. Both therapies aim to address thyroid eye disease (TED) and represent potential foundational treatments for patients. Financial results for Q4 and full year 2025 were also disclosed, highlighting the company's ongoing development efforts.
Read more →VRDNViridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - January 8, 2026
Viridian Therapeutics announced the approval of non-qualified stock options for a new employee as part of its inducement grants under Nasdaq Listing Rule 5635(c)(4). The grants, totaling 16,650 shares, will vest over four years. The company is also progressing with its late-stage clinical trials for treatments targeting thyroid eye disease.
Read more →VRDNViridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease
Viridian Therapeutics announced that the FDA has accepted its Biologics License Application for veligrotug, a treatment for thyroid eye disease, granting it Priority Review. This designation shortens the review timeline to six months and reflects the drug's potential to significantly improve treatment outcomes. The BLA is supported by positive phase 3 trial data demonstrating robust efficacy and safety.
Read more →VRDNViridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent Progress - Completed a comprehensive set of financing transactions in October 2025, securing access to up to $889 million of potent
Viridian Therapeutics reported significant financial results and operational advancements for Q3 2025. They have secured access to up to $889 million through financing transactions, which positions them well for future growth. The company has successfully submitted a BLA for their drug veligrotug, aimed at treating thyroid eye disease, with a planned commercial launch in mid-2026, pending approval. Additionally, the company's trials for VRDN-003 are showing strong enrollment and promising results.
Read more →VRDNViridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial Results - Robust execution with multiple upcoming near-term milestones, including planned Biologics License Application (BLA) sub
Viridian Therapeutics has reported positive developments in its second-quarter financial results, focusing on its lead candidate, veligrotug, which is on track for a Biologics License Application submission in the second half of 2025. The company announced its Breakthrough Therapy Designation by the FDA for veligrotug, demonstrating its potential to outperform existing treatments. Additionally, Viridian has entered an exclusive licensing agreement with Kissei Pharmaceutical to commercialize veligrotug and another candidate in Japan. The company projects a strong cash position supporting its operational runway into 2027 as clinical trials for its portfolio progress.
Read more →VRDNViridian Therapeutics Announces Collaboration and License Agreement with Kissei Pharmaceutical to Develop and Commercialize Veligrotug and VRDN-003 in Japan with an Upfront Payment of $70 Million and up to $315 Million i
Viridian Therapeutics has entered into a collaboration and license agreement with Kissei Pharmaceutical to develop and commercialize two of its drug candidates, veligrotug and VRDN-003, specifically targeting thyroid eye disease (TED) in Japan. Under the terms, Viridian will receive $70 million upfront, with an additional potential $315 million tied to development and commercial milestones. Kissei will take charge of all development, regulatory, and commercialization efforts in Japan. Both companies aim to quickly advance these promising treatment options to meet the needs of TED patients, leveraging Kissei's expertise in rare diseases.
Read more →VRDNViridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED) - 70% of patients treated with veligrotug in THRIVE w
Viridian Therapeutics announced positive long-term durability data from its Phase 3 THRIVE clinical trial for veligrotug, an anti-IGF-1R antibody, aimed at treating active thyroid eye disease (TED). By week 52, 70% of patients who responded positively at week 15 maintained their improvement, reinforcing the drug's clinical profile. The company has received Breakthrough Therapy Designation, enhancing its regulatory pathway, with the Biologics License Application submission anticipated in late 2025 and a potential commercial launch planned for 2026.
Read more →VRDNViridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results - Biologics License Application (BLA) submission for veligrotug on track for second half 2025 with potential for U.S. laun
Viridian Therapeutics recently highlighted its achievements and financial results for Q1 2025. The company is progressing toward a Biologics License Application (BLA) submission for veligrotug, anticipated in the second half of 2025, with a projected U.S. launch in 2026. Additionally, the firm is on track to deliver topline data from phase 3 trials for VRDN-003 in 2026 and has a well-established cash position expected to sustain operations through 2027. Furthermore, the recent appointment of Jeff Ajer to the Board of Directors is seen as a positive step toward enhancing commercial capabilities.
Read more →VRDNViridian Therapeutics Appoints Jeff Ajer to its Board of Directors - Mr. Ajer was most recently Chief Commercial Officer at BioMarin - Waltham, Mass.
Viridian Therapeutics has appointed Jeff Ajer to its Board of Directors, bringing over 25 years of experience in commercialization for rare diseases and specialty medicines. Ajer's expertise includes leadership roles at BioMarin Pharmaceutical, where he played a crucial role in launching five brands. The company is currently advancing its promising treatment veligrotug towards BLA submission and has reported positive results from its global phase 3 clinical trials. Additionally, Viridian is focused on enhancing its operations and pipeline through the induction of new personnel.
Read more →VRDNViridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results - Reported positive topline phase 3 data for veligrotug from both THRIVE and THRIVE-2 in patients with acti
Viridian Therapeutics recently highlighted its successful progress in 2024, particularly the positive topline data from phase 3 trials for veligrotug in patients with thyroid eye disease. The company has a robust financial position, ensuring cash runway into 2027, and is well-positioned for upcoming Biologics License Applications. Viridian is also advancing its FcRn inhibitor programs, with significant milestones expected in the coming years. Additionally, Radhika Tripuraneni has been appointed as the new Chief Medical Officer, which may enhance clinical development efforts.
Read more →VRDNViridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease - Veligrotug met all primary and secondary endpoints with high statist
Viridian Therapeutics has announced positive topline results from its Phase 3 THRIVE-2 clinical trial for Veligrotug, showing significant efficacy in treating chronic thyroid eye disease (TED). The treatment met all primary and secondary endpoints, achieving a responder rate of 56% for proptosis and a diplopia complete resolution rate of 32%. With a patient completion rate of 94%, the drug shows a favorable safety profile as well. Viridian plans to submit a Biologics License Application (BLA) for Veligrotug in the second half of 2025, with additional studies for another compound, VRDN-003, also underway.
Read more →VRDNViridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data - Reported positive topline phase 3 data for veligrotug from THRIVE in patients with active thyroid eye disea
Viridian Therapeutics reported strong financial results for Q3 2024, highlighting positive phase 3 data for veligrotug in active thyroid eye disease. The company is advancing its pipeline with new global phase 3 trials for VRDN-003 and plans for IND submissions for several candidates by the end of 2025 and 2024. Financial liquidity has improved following a public offering, providing cash reserves that bolster operational capabilities into 2027. The CEO emphasized the promising outlook of the FcRn inhibitor portfolio, positioning the company for further growth and innovation.
Read more →VRDNViridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease - Veligrotug (VRDN-001) achieved all primary and secondary end
Viridian Therapeutics announced positive topline results from its Phase 3 THRIVE clinical trial for Veligrotug (VRDN-001) in patients with active thyroid eye disease. The trial demonstrated that Veligrotug met all primary and secondary endpoints, with a responder rate of 70% and significant improvements in other clinical measures. There were no treatment-related serious adverse events reported, indicating a favorable safety profile. The company anticipates submitting a biologics license application (BLA) for Veligrotug in the second half of 2025.
Read more →VRDNViridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2024 Financial Results - THRIVE VRDN-001 global phase 3 clinical trial in active thyroid eye disease (TED) remains on track for topline readout
Viridian Therapeutics has reported progress in its clinical trials and financial results for the second quarter of 2024. The company confirmed that its THRIVE and THRIVE-2 global phase 3 trials for VRDN-001 have exceeded enrollment targets and are on track for topline readouts. Additionally, Viridian has plans for new investigational drug submissions and has solid financial resources with over $571 million in cash, which ensures operations into 2026. The company's continued advancement in its thyroid eye disease portfolio highlights its commitment to pioneering innovative treatments.
Read more →VRDNCorporate Presentation July 2024 Cautionary note regarding forward-looking statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Thes
Viridian is actively developing several product candidates, including VRDN-001, VRDN-003, VRDN-006, and VRDN-008, targeting conditions like Thyroid Eye Disease. The company has outlined upcoming milestones and maintains a cash runway into the second half of 2026. However, its forward-looking statements emphasize various risks, uncertainties, and potential delays in regulatory approvals and clinical development timelines. Upcoming events include pivotal trials and expected topline results throughout 2024 and 2025, which will be crucial for the company's future performance.
Read more →VRDNViridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results - THRIVE VRDN-001 global phase 3 clinical trial in active thyroid eye disease (TED) completed and exceeded its target for
Viridian Therapeutics has reported its first quarter 2024 financial results and highlighted significant advancements in its clinical trials for thyroid eye disease (TED). The THRIVE VRDN-001 global phase 3 trial has completed enrollment ahead of schedule, with topline results anticipated in September 2024. Additionally, a positive meeting with the FDA regarding the pivotal program for VRDN-003 has set it on track for initiation in mid-2024. The company's commitment to developing innovative therapies for TED and FcRn inhibitors was emphasized, showcasing readiness for key milestones ahead.
Read more →VRDNViridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results - VRDN-001 Phase 3 THRIVE and THRIVE-2 topline clinical data readouts are expected for mid-year 2024 and ye
Viridian Therapeutics reported significant advancements in its clinical programs for the fourth quarter and full year of 2023. The company is preparing for topline clinical data readouts for VRDN-001 and VRDN-003 in 2024. Additionally, Viridian unveiled its FcRn inhibitor portfolio, consisting of VRDN-006 and VRDN-008, with ongoing studies expected to initiate shortly. The company reported a healthy cash balance and successful financing efforts, solidifying its financial position for future operations.
Read more →VRDNViridian Therapeutics to Present Key 2024 Corporate Priorities at J.P. Morgan Healthcare Conference - VRDN-001 topline clinical results for THRIVE and THRIVE-2 on track for mid-2024 and year-end 2024 in patients with act
Viridian Therapeutics has announced key corporate priorities for 2024, including the expected topline clinical results for its VRDN-001 asset in two Phase 3 studies for thyroid eye disease (TED), slated for mid-2024 and year-end 2024. The company aims to initiate a pivotal study for VRDN-003 by mid-2024, pending regulatory alignment. Additionally, Viridian plans to submit an Investigational New Drug Application for its FcRn inhibitor portfolio, including VRDN-006 by the end of 2024. The promotion of Dr. Thomas Ciulla to Chief Medical Officer highlights the company's commitment to its clinical development efforts.
Read more →VRDNViridian Therapeutics Announces Positive Clinical Data in Healthy Volunteer Study and Selects VRDN-003 as Potential Best-in-Class Subcutaneous anti-IGF-1R Program with Extended Half-Life for Pivotal Development in Thyroi
Viridian Therapeutics announced positive clinical data for VRDN-003, its lead subcutaneous anti-IGF-1R therapy for thyroid eye disease. The Phase 1 study in healthy volunteers showed that VRDN-003 achieved an extended half-life of 40-50 days and can be dosed as infrequently as every eight weeks. The company plans to initiate pivotal clinical trials for VRDN-003 in mid-2024, pending regulatory alignment, marking a significant step in treatment options for thyroid eye disease patients.
Read more →VRDNViridian Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update - THRIVE and THRIVE-2 clinical trials are continuing to enroll active and chronic thyroid eye disease (TED) patients; expec
Viridian Therapeutics has reported third-quarter 2023 financial results, highlighting ongoing enrollment in its THRIVE and THRIVE-2 clinical trials for thyroid eye disease (TED). The company expects to deliver topline results for these trials in 2024 and has successfully raised approximately $185 million to fund its pipeline development. Additionally, Viridian is advancing a preclinical portfolio of novel neonatal Fc receptor (FcRn) inhibitors. Despite these advancements, the company recorded a net loss of $47.7 million for the quarter, indicating challenges alongside its progress.
Read more →VRDNViridian Therapeutics Appoints New Chief Executive Officer, Unveils Next Generation FcRn Inhibitor Programs and Announces $185 Million Private Placement Financing Stephen Mahoney appointed President and Chief Executive O
Viridian Therapeutics has appointed Stephen Mahoney as President and CEO, aiming to advance its strategic goals, particularly in developing next-generation FcRn inhibitors. The company also unveiled a promising portfolio of FcRn inhibitors designed to treat autoimmune diseases and expects to submit an IND by the end of 2024. Additionally, Viridian has raised $185 million through private placement financing to support its expanded pipeline and operating expenses into 2026. The firm's clinical trials for thyroid eye disease are on schedule, with key data expected in mid-2024.
Read more →VRDNCorporate Overview July 2023 Cautionary note regarding forward-looking statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These st
Viridian Therapeutics provided a corporate overview highlighting forward-looking statements related to its investigational therapies for Thyroid Eye Disease. The company discussed the current status of its clinical programs, particularly VRDN-001, and addressed the risks associated with efficacy, safety, regulatory approvals, and financial sustainability. The presentation emphasized the uncertainties in clinical trial outcomes and the market potential for its therapies. As of now, Viridian has a cash runway into the second half of 2025 and continues to explore opportunities in treatment for this rare disease.
Read more →VRDNViridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED) - VRDN-001 data demonstrated clinically meaningful and rapid improvement in signs and s
Viridian Therapeutics has announced encouraging results from its ongoing Phase 1/2 trial of VRDN-001, an investigational treatment for chronic thyroid eye disease (TED). The data showed significant improvements in symptoms after just two infusions of the drug. The company also plans to amend its Phase 3 THRIVE trial to include a more streamlined dosing regimen, aiming to expedite treatment for patients. Additionally, Viridian is preparing to initiate the THRIVE-2 trial and further develop its subcutaneous candidates.
Read more →VRDNViridian Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
Viridian Therapeutics reported its first quarter 2023 financial results, highlighting upcoming topline data from the VRDN-001 proof-of-concept study in chronic thyroid eye disease (TED) expected in June/July. The company plans to initiate its THRIVE-2 Phase 3 trial and has added several senior executives to its leadership team. Viridian is advancing multiple candidates for TED and aims to develop a subcutaneous formulation for easier administration.
Read more →VRDNViridian Therapeutics Announces Partnership with Drug Delivery Innovator Enable Injections
Viridian Therapeutics has partnered with Enable Injections to enhance drug delivery for its preclinical programs outside of thyroid eye disease. The collaboration aims to utilize Enable's enFuse technology, which offers a hands-free, discreet method for patients to self-administer medication. This partnership reflects Viridian's commitment to patient-centric innovation and improving treatment convenience.
Read more →VRDNViridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Viridian Therapeutics announced the grant of non-qualified stock options to two new employees as part of its inducement strategy under Nasdaq Listing Rule 5635(c)(4). The grants, totaling 96,000 shares, will vest over four years. The company is also progressing its clinical trials for thyroid eye disease, including a Phase 3 trial for VRDN-001.
Read more →VRDNViridian Therapeutics to Webcast First Quarter 2023 Financial Results and Corporate Update on May 9, 2023
Viridian Therapeutics will host a webcast on May 9, 2023, to discuss its first quarter financial results and provide a corporate update. The company is advancing several candidates for thyroid eye disease, including a global Phase 3 trial for VRDN-001. The webcast will be accessible on their website, and a replay will be available post-event.
Read more →VRDNUPDATE – Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Association for Research in Vision and Ophthalmology
Viridian Therapeutics announced that it will present updated clinical and preclinical data on its thyroid eye disease (TED) pipeline at the ARVO 2023 meeting. Key highlights include a platform presentation on the Phase 1/2 trial of VRDN-001 and poster presentations on VRDN-002 and VRDN-003. The data emphasizes the potential of these investigational therapies in treating TED.
Read more →VRDNViridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Association for Research in Vision and Ophthalmology
Viridian Therapeutics has announced that it will present significant updates on its thyroid eye disease (TED) research at the upcoming ARVO 2023 annual meeting. The company will highlight data from a Phase 1/2 clinical trial of its lead candidate, VRDN-001, as well as new preclinical findings for its next-generation therapies, VRDN-002 and VRDN-003. These investigations aim to explore their potential to navigate the treatment landscape for TED, which affects many patients. The presentations are scheduled for April 23-27, 2023, in New Orleans, Louisiana.
Read more →VRDNViridian Therapeutics Appoints Tony Casciano as Chief Commercial Officer
Viridian Therapeutics has appointed Tony Casciano as Chief Commercial Officer, marking a significant milestone in the company's growth. Casciano brings over 20 years of experience in sales and marketing within the biopharma industry. His leadership is expected to enhance Viridian's commercial operations as the company advances its therapies for thyroid eye disease, including a Phase 3 trial for VRDN-001.
Read more →VRDNViridian Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates - Positive data reported from ongoing Phase 1/2 trial evaluating low-dose VRDN-001 in patients with thyroid
Viridian Therapeutics has reported its fourth quarter and full year 2022 financial results, highlighting advancements in its thyroid eye disease (TED) program. The company shared positive results from ongoing trials of its lead product candidate, VRDN-001, and has initiated the THRIVE Phase 3 trial for active TED patients. Forward-looking statements indicate expectations for further data releases in 2023, while also noting challenges related to financial losses and uncertainty in clinical outcomes.
Read more →VRDNViridian Therapeutics Announces Presentations at the 49th Annual Meeting of the North American Neuro-Ophthalmology Society
Viridian Therapeutics, Inc. announced multiple presentations for its investigational therapies VRDN-001 and VRDN-002 at the 49th Annual Meeting of the North American Neuro-Ophthalmology Society. The highlight includes an oral presentation of Phase 1/2 trial data for VRDN-001, which is a treatment for thyroid eye disease. Additionally, several poster presentations will address trial design and early-stage data on the company's pipeline candidates. This event is seen as pivotal for strengthening confidence in their ongoing clinical efforts.
Read more →VRDNViridian Therapeutics to Webcast Fourth Quarter and Full Year 2022 Financial Results on March 8, 2023
Viridian Therapeutics, Inc. plans to host a webcast on March 8, 2023, to discuss its fourth quarter and full year 2022 financial results. The event will allow investors to gain insights into the company's financial performance and progress. Viridian is advancing multiple drug candidates, including VRDN-001, targeting thyroid eye disease, with a global Phase 3 trial in the pipeline. The webcast reflects the company's commitment to maintain clear communication with its stakeholders.
Read more →VRDNViridian Therapeutics to Participate in Cowen’s 43rd Annual Health Care Conference
Viridian Therapeutics, Inc. announced its participation in Cowen’s 43rd Annual Health Care Conference scheduled for March 8, 2023, at 1:30 p.m. ET in Boston. The presentation will showcase the company's commitment to developing advanced treatments for serious and rare diseases. Currently, Viridian is focused on its lead candidate, VRDN-001, which is undergoing trials for thyroid eye disease. A live webcast of the presentation will be available on their website, along with a replay after the event.
Read more →VRDNViridian Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference
Viridian Therapeutics announced participation in the SVB Securities Virtual Global Biopharma Conference on February 15, 2023. Senior management will engage in a fireside chat during the event, highlighting the company's focus on rare diseases. Viridian is advancing various therapeutic candidates for thyroid eye disease and has begun a global Phase 3 trial for its lead candidate, VRDN-001. The company is positioned strongly within its therapeutic focus areas and aims to offer best-in-class medicines.
Read more →VRDNViridian Appoints Scott Myers as President and Chief Executive Officer - Transition highlights Viridian s progression towards becoming a fully-integrated biopharmaceutical company Waltham, Mass.
Viridian Therapeutics has appointed Scott Myers as its new President and Chief Executive Officer, effective February 6, 2023. Myers, who has over 30 years of experience in the biopharmaceutical industry, succeeds co-founder Jonathan Violin, Ph.D. This leadership change is expected to assist Viridian in progressing towards becoming a fully-integrated biopharmaceutical company. The company is currently advancing clinical trials, including a Phase 3 trial targeting thyroid eye disease (TED).
Read more →VRDNViridian Appoints Scott Myers as President and Chief Executive Officer
Viridian Therapeutics has appointed Scott Myers as President and CEO, effective February 6, 2023, succeeding co-founder Jonathan Violin. Myers brings over 30 years of experience in biopharmaceuticals and has previously held executive positions at various companies. His appointment comes as the company moves forward with a Phase 3 trial for thyroid eye disease and seeks to evolve into a fully-integrated biopharmaceutical entity. Viridian also granted an inducement award to Myers, including stock options and restricted stock units.
Read more →VRDNViridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Viridian Therapeutics, Inc. announced the approval of non-qualified stock options for four new employees, totaling 332,000 shares. These grants were made as part of the company's strategy to attract talent and are consistent with Nasdaq Listing Rule 5635(c)(4). The options will vest over four years, incentivizing the new hires to contribute to the company's objectives. Viridian continues to advance its therapeutics for serious diseases, including ongoing trials for thyroid eye disease treatments.
Read more →VRDNViridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating Low Dose VRDN-001 in Patients with Thyroid Eye Disease (TED) - Significant and rapid improvement in both signs and symptoms of TED aft
Viridian Therapeutics has announced encouraging results from the Phase 1/2 trial of VRDN-001, an anti-IGF-1R antibody for thyroid eye disease (TED). The trial revealed significant improvements in proptosis and symptoms for patients treated with low doses. Notably, 71% of participants responded positively in terms of proptosis, and the treatment was well tolerated with no serious adverse events reported. This data supports the further development of viridian’s subcutaneous therapies aiming for easier administration.
Read more →VRDNViridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating Low Dose VRDN-001 in Patients with Thyroid Eye Disease (TED)
Viridian Therapeutics announced positive topline data from its Phase 1/2 trial of VRDN-001 for treating thyroid eye disease (TED). The trial showed a rapid and significant improvement in both clinical symptoms and patient responses, particularly with the 3 mg/kg dose cohort. Safety data indicated a favorable profile with no severe adverse events reported. The results bolster confidence in the upcoming development of Viridian's next-generation treatments, VRDN-002 and VRDN-003.
Read more →VRDNViridian Therapeutics to Webcast Presentation at the 41st Annual J.P. Morgan Healthcare Conference
Viridian Therapeutics, a biopharmaceutical company, will present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023. CEO Jonathan Violin will discuss the company's corporate priorities and ongoing projects, particularly concerning their therapies for thyroid eye disease. A live webcast of the presentation and Q&A session will be available on the company's website. Viridian is focused on developing innovative treatments for serious and rare diseases.
Read more →VRDNViridian Therapeutics Announces First Patient Enrolled in the ‘THRIVE’ Phase 3 Trial in Patients With Thyroid Eye Disease
- The global THRIVE Phase 3 trial will be conducted in approximately 50 centers across North America and Europe - - Topline results for the THRIVE Phase 3 trial are expected in the middle of 2024 – WALTHAM, Mass., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (N
Read more →VRDNViridian Therapeutics To Participate In The Evercore ISI HealthCONx Conference
WALTHAM, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced that senior management will participate in
Read more →VRDNViridian Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Updates
- Significant and rapid improvement in both signs and symptoms of TED at week 6 after two infusions of 20 mg/kg VRDN-001; generally consistent with 10mg/kg results at week 6 - - Global Phase 3 THRIVE clinical program initiated - - Ended 3Q 2022 with cash, cash equivalents, and
Read more →VRDNViridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)
- Significant and rapid improvement in both signs and symptoms of TED after two infusions of 20 mg/kg VRDN-001, generally consistent with 10 mg/kg results at week 6 - - Global Phase 3 THRIVE clinical program initiated - - Across all VRDN-001 treated patients to date: 75% were p
Read more →VRDNViridian Therapeutics to Participate in Guggenheim 4th Annual Neuro/Immunology Conference on November 15th
WALTHAM, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced that management will participate in the Gu
Read more →VRDNViridian Therapeutics to Report Third Quarter 2022 Financial Results and Host Conference Call on November 14, 2022
WALTHAM, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced it will report its financial results from
Read more →VRDNViridian Presents Positive Clinical Data from Ongoing VRDN-001 Phase 1/2 Trial in Active Thyroid Eye Disease (TED) Patients During Late-Breaking Presentations at the American Thyroid Association (ATA) 91st Annual Meeting
- Clinical and in vitro data presented in three late-breaking presentations at ATA provide emerging evidence of VRDN-001 efficacy and differentiation - - Full 10 mg/kg cohort data presented at ATA, 20 mg/kg and 3 mg/kg cohort data on track for 4Q22 - - Pivotal program for VRDN-
Read more →VRDNViridian Therapeutics Announces Presentations at the American Thyroid Association 91st Annual Meeting
- Three late-breaking presentations to feature emerging evidence of VRDN-001 efficacy and differentiation - - VRDN-001 10mg/kg proof of concept data from ongoing Phase 1/2 trial in Thyroid Eye Disease selected for late-breaking presentation - - Mechanistic characterization of V
Read more →VRDNViridian Therapeutics Announces Exercise in Full and Closing of Underwriters’ Option to Purchase Additional Shares in Public Offering
WALTHAM, Mass., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced that it has issued an additional 1,725,000
Read more →VRDNViridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock
WALTHAM, Mass., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced the pricing of an upsized underwritten pub
Read more →VRDNViridian Announces Positive Initial Clinical Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)
- Significant and rapid improvement in both signs and symptoms of TED at week 6 after two infusions of 10mg/kg VRDN-001 - - Proptosis response achieved by 83% of patients with a mean reduction of 2.4mm from baseline - - Clinical Activity Score (CAS) of 0 or 1 achieved by 83% of
Read more →VRDNVIRIDIAN THERAPEUTICS REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATES - Positive initial clinical data from ongoing Phase 1/2 Trial evaluating VRDN-001 in patients with Thyroid Eye Disease (T
VIRIDIAN THERAPEUTICS REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATES - Positive initial clinical data from ongoing Phase 1/2 Trial evaluating VRDN-001 in patients with Thyroid Eye Disease (TED) - - VRDN-002 achieved a substantially extended half-
Read more →VRDNViridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock
WALTHAM, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced that it has commenced an underwritten publ
Read more →VRDNViridian Therapeutics to Report Second Quarter 2022 Financial Results and Host Conference Call on August 15, 2022
WALTHAM, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced it will report its financial results from
Read more →VRDNViridian Therapeutics Appoints Carrie Melvin as Chief Operating Officer
WALTHAM, Mass., June 23, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced the appointment of Carrie Melvin as Chief
Read more →VRDNViridian Therapeutics to Participate in June Investor Conferences
WALTHAM, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced that Jonathan Violin, Ph.D., President and
Read more →VRDNVIRIDIAN THERAPEUTICS REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATES Phase 1/2 clinical trial for VRDN-001 currently recruiting Thyroid Eye Disease (TED) patients at sites in the U.S. and Can
VIRIDIAN THERAPEUTICS REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATES Phase 1/2 clinical trial for VRDN-001 currently recruiting Thyroid Eye Disease (TED) patients at sites in the U.S. and Canada; top line proof of concept data expected in the third
Read more →VRDNViridian Therapeutics to Report First Quarter 2022 Financial Results and Host Conference Call on May 12, 2022
WALTHAM, Mass., May 03, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced it will report its financial results from t
Read more →VRDNViridian Therapeutics to Participate in The 21st Annual Needham Virtual Healthcare Conference on April 14
WALTHAM, Mass., April 06, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced that Jonathan Violin, Ph.D., President an
Read more →VRDNViridian Therapeutics Secures Flexible Credit Facility for Up to $75 Million From Hercules Capital
WALTHAM, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced that the Company has entered into a debt
Read more →VRDNViridian Therapeutics Doses First Subject in First-in-Human Clinical Trial Evaluating VRDN-002, a Next Generation IGF-1R Antibody for the Treatment of Thyroid Eye Disease
- VRDN-002 incorporates clinically validated half-life extension technology to support development as a low volume subcutaneous injection that could broaden settings of care - - Top line results from the Phase 1 trial of VRDN-002 expected mid-year - WALTHAM, Mass., March 21, 20
Read more →VRDNViridian Therapeutics to Participate in 32nd Annual Oppenheimer Healthcare Conference on March 15
WALTHAM, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced that Jonathan Violin, Ph.D., President an
Read more →VRDNVIRIDIAN THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATES Ongoing Phase 1/2 clinical trial for VRDN-001, an IGF-1R antibody for the treatment of Thyroid Eye Disease,
VIRIDIAN THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATES Ongoing Phase 1/2 clinical trial for VRDN-001, an IGF-1R antibody for the treatment of Thyroid Eye Disease, is on track to report top line proof of concept data in
Read more →VRDNViridian Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Host Investor Conference Call on March 10, 2022
WALTHAM, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced it will report its financial results from
Read more →VRDNViridian Therapeutics to Participate in the SVB Leerink 2022 Global Healthcare Conference on February 18
WALTHAM, Mass., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced that Jonathan Violin, Ph.D., President and
Read more →VRDNViridian Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate Clinical Development of VRDN-002, a Next Generation IGF-1R Antibody for the Treatment of Thyroid Eye Disease
- VRDN-002 incorporates clinically validated half-life extension technology to support development as a low volume subcutaneous injection - - Company expects to report top line VRDN-002 Phase 1 clinical data in mid-2022 - WALTHAM, Mass., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Viridi
Read more →VRDNViridian Therapeutics Submits Investigational New Drug Application for VRDN-002 to the U.S. Food and Drug Administration
- VRDN-002 is a novel anti-IGF-1R monoclonal antibody for thyroid eye disease and incorporates half-life extension technology designed to improve dosing and administration - - Company expects to report top line VRDN-002 phase 1 clinical data in mid-2022 - WALTHAM, Mass., Jan. 0
Read more →VRDNViridian Therapeutics Announces First Subject Dosed in Phase 1/2 Clinical Trial of VRDN-001 for Thyroid Eye Disease (TED)
- VRDN-001 targets and blocks IGF-1R, the only mechanism of action proven to deliver efficacy in TED - - Trial is on track to deliver top line proof of concept clinical data in 2Q 2022 - WALTHAM, Mass., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN
Read more →VRDNViridian Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for VRDN-001, an IGF-1R Antibody for the Treatment of Thyroid Eye Disease (TED)
Phase 1/2 proof of concept trial for VRDN-001 is expected to report top line clinical data in the second quarter of 2022 WALTHAM, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN) (the “Company” or “Viridian”), a biotechnology company advancing
Read more →VRDNVIRIDIAN THERAPEUTICS REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATES Submitted an investigational new drug (IND) application to the FDA for VRDN-001, an IGF-1R antibody for the treatment of T
VIRIDIAN THERAPEUTICS REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATES Waltham, Mass., November 4, 2021 Viridian Therapeutics, Inc. (NASDAQ: VRDN) (the Company or Viridian ), a biotechnology company advancing new treatments for patients suffering from
Read more →VRDNViridian Therapeutics to Present at Upcoming Investor Conferences
WALTHAM, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies, today announced that Jonathan Violin, Ph.D., President
Read more →VRDNViridian Therapeutics Submits Investigational New Drug Application for VRDN-001, an IGF-1R antibody for the treatment of Thyroid Eye Disease, to the U.S. Food and Drug Administration
- VRDN-001 program remains on track for key proof of concept clinical data in Thyroid Eye Disease patients in the second quarter of 2022 - WALTHAM, Mass., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company advancing new trea
Read more →VRDNViridian Therapeutics to Present Preclinical Data on VRDN-001 and VRDN-002 at the 90th Annual Meeting of the American Thyroid Association
WALTHAM, Mass., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but underserved by today's therapies, announced today that two posters featuring precli
Read more →VRDNViridian Therapeutics Announces Closing of Public Offering of Shares of Common Stock and Preferred Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
WALTHAM, Mass., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but underserved by today's therapies, today announced the closing of an underwritten pu
Read more →VRDNViridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock and Preferred Stock
WALTHAM, Mass., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but underserved by today's therapies, today announced the pricing of an underwritten pu
Read more →VRDNVIRIDIAN THERAPEUTICS REPORTS SECOND QUARTER 2021 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATES Completed a successful pre-IND meeting with the FDA for VRDN-001, a differentiated monoclonal antibody targeting IGF-1R f
VIRIDIAN THERAPEUTICS REPORTS SECOND QUARTER 2021 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATES Waltham, Mass., August 11, 2021 Viridian Therapeutics, Inc. (Nasdaq: VRDN) ( the Company or Viridian ), a biopharmaceutical company advancing new treatments for patients sufferin
Read more →VRDNViridian Therapeutics to Participate in the Wedbush PacGrow Healthcare Virtual Conference
BOULDER, Colo., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies, today announced that Jonathan Violin, Ph.D., Presi
Read more →VRDNViridian Therapeutics Appoints Kristian Humer as Chief Financial Officer and Chief Business Officer
BOULDER, Colo., July 26, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies, today announced the appointment of Kristian Humer
Read more →VRDNVIRIDIAN
VIRIDIAN THERAPEUTICS APPOINTS KRISTIAN HUMER AS CHIEF FINANCIAL OFFICER AND CHIEF BUSINESS OFFICER BOULDER, Colo., July 26, 2021 (GLOBE NEWSWIRE) Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serio
Read more →VRDNViridian Therapeutics Appoints Jennifer Moses, CPA to the Board of Directors and as Chair of the Audit Committee
BOULDER, Colo., July 15, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies, today announced the appointment of Jennifer Moses,
Read more →VRDNVIRIDIAN THERAPEUTICS APPOINTS JENNIFER MOSES
VIRIDIAN THERAPEUTICS APPOINTS JENNIFER MOSES, CPA TO THE BOARD OF DIRECTORS AND AS CHAIR OF THE AUDIT COMMITTEE BOULDER, Colo., July 15, 2021 (GLOBE NEWSWIRE) Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company advancing new treatments for patients sufferi
Read more →VRDNViridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BOULDER, Colo., July 14, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (Nasdaq: VRDN) (“the “Company” or “Viridian”), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but underserved by current therapies, today announced tha
Read more →VRDNViridian Therapeutics to Present at the Ladenburg Thalmann 2021 Healthcare Conference
BOULDER, Colo., July 07, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies, today announced that Jonathan Violin, Ph.D., Presi
Read more →VRDNViridian Therapeutics to Participate in the JMP Securities Life Sciences Conference
BOULDER, Colo., June 10, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies, today announced that Jonathan Violin, Ph.D., Presi
Read more →VRDNViridian Therapeutics to Participate in Upcoming Investor Conferences
BOULDER, Colo., May 14, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies, today announced that Jonathan Violin, Ph.D., Presid
Read more →VRDNVIRIDIAN THERAPEUTICS REPORTS FIRST QUARTER 2021 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATES VRDN-001 and VRDN-002 programs for Thyroid Eye Disease (TED) progressing on track for IND filings in fourth quarter of 202
VIRIDIAN THERAPEUTICS REPORTS FIRST QUARTER 2021 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATES VRDN-001 and VRDN-002 programs for Thyroid Eye Disease (TED) progressing on track for IND filings in fourth quarter of 2021 Reported $117 million in cash, cash equivalents and sho
Read more →VRDNVIRIDIAN THERAPEUTICS REPORTS 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATES Progressed lead programs VRDN-001 and VRDN-002 towards clinical trials in Thyroid Eye Disease (TED) both IND filings expected by the end
VIRIDIAN THERAPEUTICS REPORTS 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATES Progressed lead programs VRDN-001 and VRDN-002 towards clinical trials in Thyroid Eye Disease (TED) both IND filings expected by the end of 2021 Completed integration and name change to Viridia
Read more →VRDNViridian Therapeutics To Host Conference Call Discussing Fourth Quarter And Full Year 2020 Results And Corporate Update
BOULDER, Colo., March 09, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies, today announced that it will host a conference ca
Read more →VRDNViridian Therapeutics to Present at Three Upcoming Investor Conferences
BOULDER, Colo., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a development-stage biopharmaceutical company, today announced that Jonathan Violin, Ph.D., President and Chief Executive Officer of Viridian, will present a company overview at the foll
Read more →VRDNmiRagen Enters into License Agreement with Xencor for use of Xtend Antibody Technology for Investigational Antibodies to Treat Thyroid Eye Disease Company obtains exclusive rights to develop and commercialize antibody th
miRagen Enters into License Agreement with Xencor for use of Xtend Antibody Technology for Investigational Antibodies to Treat Thyroid Eye Disease Company obtains exclusive rights to develop and commercialize antibody therapeutics targeting insulin-like growth factor-1 receptor
Read more →VRDNMIRAGEN REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATES Recently completed acquisition of Viridian Therapeutics, including an anti-IGF-1R monoclonal antibody, VRDN-001, for the potential treat
MIRAGEN REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATES Recently completed acquisition of Viridian Therapeutics, including an anti-IGF-1R monoclonal antibody, VRDN-001, for the potential treatment of thyroid eye disease (TED) Private placement finan
Read more →VRDNmiRagen Therapeutics, Inc. Announces Acquisition of Viridian Therapeutics, Inc.
miRagen Therapeutics, Inc. Announces Acquisition of Viridian Therapeutics, Inc. Acquisition includes clinical stage anti-IGF-1R monoclonal antibody, VRDN-001, intended for the treatment of thyroid eye disease (TED) Company plans to use private placement financing proceeds of
Read more →VRDNmiRagen Announces Internal Review of Preliminary Topline Data for the Phase 2 SOLAR Clinical Trial of Cobomarsen in Patients with Cutaneous T-Cell Lymphoma (CTCL) - - - miRagen decides to discontinue further internal dev
miRagen Announces Internal Review of Preliminary Topline Data for the Phase 2 SOLAR Clinical Trial of Cobomarsen in Patients with Cutaneous T-Cell Lymphoma (CTCL) miRagen decides to discontinue further internal development of cobomarsen BOULDER, Colo., October 5, 2020 - miRagen
Read more →VRDNmiRagen Announces Leadership Transition and Review of Strategic Alternatives Lee Rauch appointed President and CEO, following resignation by William Marshall miRagen will undertake an in-depth review of its portfolio Lad
miRagen Announces Leadership Transition and Review of Strategic Alternatives Lee Rauch appointed President and CEO, following resignation by William Marshall miRagen will undertake an in-depth review of its portfolio Ladenburg Thalmann engaged as financial advisor BOULDER, Co
Read more →VRDNMIRAGEN REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES Progress on next generation microRNA-29 mimic for use in pulmonary fibrosis (MRG-229) includes new preclinical data additional NIH grant
MIRAGEN REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES Progress on next generation microRNA-29 mimic for use in pulmonary fibrosis (MRG-229) includes new preclinical data additional NIH grant funding triggered Exploratory preclinical safety and phar
Read more →VRDNCOBOMARSEN RECEIVES ORPHAN DRUG DESIGNATION FROM THE U.S. FDA FOR THE TREATMENT OF T-CELL LYMPHOMA Boulder, Colorado
COBOMARSEN RECEIVES ORPHAN DRUG DESIGNATION FROM THE U.S. FDA FOR THE TREATMENT OF T-CELL LYMPHOMA Boulder, Colorado July 23, 2020 miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted the
Read more →VRDNmiRagen Announces Encouraging Preclinical Safety and Efficacy Data for its Next-generation miR-29 Replacement Product Candidate Intended for the Treatment of Idiopathic Pulmonary Fibrosis - - - Key Opinion Leader call on
miRagen Announces Encouraging Preclinical Safety and Efficacy Data for its Next-generation miR-29 Replacement Product Candidate Intended for the Treatment of Idiopathic Pulmonary Fibrosis Key Opinion Leader call on IPF scheduled for 11 a.m. ET on Tuesday, June 23rd BOULDER, Col
Read more →VRDNmiRagen to Host a Key Opinion Leader Call on Idiopathic Pulmonary Fibrosis on Tuesday, June 23rd - - - miRagen to announce encouraging new preclinical safety and efficacy data for MRG-229 in IPF on June 22nd and provide
miRagen to Host a Key Opinion Leader Call on Idiopathic Pulmonary Fibrosis on Tuesday, June 23rd miRagen to announce encouraging new preclinical safety and efficacy data for MRG-229 in IPF on June 22nd and provide an update on the development program during the KOL call BOULDER
Read more →VRDNMIRAGEN REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE New ATLL data presented in the first quarter Company plans to request a meeting with the FDA on a regulatory pathway for cobomarsen in AT
MIRAGEN REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE New ATLL data presented in the first quarter Company plans to request a meeting with the FDA on a regulatory pathway for cobomarsen in ATLL during Q2 2020 Additional NIH grant funding released in
Read more →VRDNMIRAGEN REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS Completed enrollment of 37 patients in the Phase 2 SOLAR trial of cobomarsen in CTCL expects to report topline data in Q3 2020 Completed initial planned
MIRAGEN REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS Completed enrollment of 37 patients in the Phase 2 SOLAR trial of cobomarsen in CTCL expects to report topline data in Q3 2020 Completed initial planned enrollment of the Phase 1 trial of cobomarsen in ATLL pat
Read more →VRDNMIRAGEN ANNOUNCES PRICING OF $15.0
MIRAGEN ANNOUNCES PRICING OF $15.0 MILLION PUBLIC OFFERING OF COMMON STOCK AND WARRANTS TO PURCHASE COMMON STOCK BOULDER, CO, February 7, 2020 miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-
Read more →VRDNMIRAGEN ANNOUNCES MAJOR CHANGES TO COMPANY'S STRATEGY Expecting topline data in Q3 2020 from truncated Phase 2 SOLAR clinical trial of cobomarsen in CTCL Pursuing guidance from FDA on a clinical development plan for cobo
MIRAGEN ANNOUNCES MAJOR CHANGES TO COMPANY'S STRATEGY Expecting topline data in Q3 2020 from truncated Phase 2 SOLAR clinical trial of cobomarsen in CTCL Pursuing guidance from FDA on a clinical development plan for cobomarsen in ATLL anticipate meeting in Q2 2020 Focusing fut
Read more →VRDNMIRAGEN REPORTS THIRD QUARTER 2019 RESULTS AND PROVIDES CORPORATE UPDATE Announced positive data from two Phase 1 clinical trials of MRG-110 Remain on track to announce interim top-line data from its Phase 2 clinical tri
MIRAGEN REPORTS THIRD QUARTER 2019 RESULTS AND PROVIDES CORPORATE UPDATE Announced positive data from two Phase 1 clinical trials of MRG-110 Remain on track to announce interim top-line data from its Phase 2 clinical trial of remlarsen in keloids by year end Implemented restru
Read more →VRDNMIRAGEN ANNOUNCES NEW CLINICAL DATA SHOWING MRG-110 POSITIVELY IMPACTED TISSUE REPAIR AND NEW BLOOD VESSEL GROWTH Data included in an oral presentation at the 15th annual meeting of the Oligonucleotide Therapeutics Socie
MIRAGEN ANNOUNCES NEW CLINICAL DATA SHOWING MRG-110 POSITIVELY IMPACTED TISSUE REPAIR AND NEW BLOOD VESSEL GROWTH Data included in an oral presentation at the 15th annual meeting of the Oligonucleotide Therapeutics Society Data supports advancing MRG-110 into additional clinica
Read more →VRDNMIRAGEN REPORTS SECOND QUARTER 2019 RESULTS REGAINS GLOBAL RIGHTS TO MRG-110 AND ANNOUNCES CORPORATE RESTRUCTURING miRagen to regain global rights to MRG-110 after Servier provides notice of portfolio realignment expects
MIRAGEN REPORTS SECOND QUARTER 2019 RESULTS REGAINS GLOBAL RIGHTS TO MRG-110 AND ANNOUNCES CORPORATE RESTRUCTURING miRagen to regain global rights to MRG-110 after Servier provides notice of portfolio realignment expects to announce Phase 1 data during the second half of 2019 C
Read more →VRDNMIRAGEN PRESENTS PRECLINICAL DATA IN PULMONARY FIBROSIS USING SECOND GENERATION MICRORNA-29 REPLACEMENT PRODUCT CANDIDATE AT THE 2019 AMERICAN THORACIC SOCIETY INTERNATIONAL CONFERENCE Second generation microRNA-29 repla
MIRAGEN PRESENTS PRECLINICAL DATA IN PULMONARY FIBROSIS USING SECOND GENERATION MICRORNA-29 REPLACEMENT PRODUCT CANDIDATE AT THE 2019 AMERICAN THORACIC SOCIETY INTERNATIONAL CONFERENCE Second generation microRNA-29 replacement shows efficacy in blunting fibrosis in the bleomycin
Read more →VRDNMIRAGEN ANNOUNCE S FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE Initiated p atient dosing in the SOLAR Phase 2 trial for cobomarsen Released u p dated c linical data from the P hase 1 trial of cobom
MIRAGEN ANNOUNCES FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE Initiated patient dosing in the SOLAR Phase 2 trial for cobomarsen Released updated clinical data from the Phase 1 trial of cobomarsen in ATLL patients Released data from preclinical studies
Read more →VRDNMIRAGEN THERAPEUTICS ANNOUNCES NEW DATA SUPPORTING THE POTENTIAL USE OF REMLARSEN TO PREVENT CORNEAL FIBROSIS AT THE 2019 ARVO MEETING Preclinical data indicate that remlarsen accelerated the healing of corneal injury wh
MIRAGEN THERAPEUTICS ANNOUNCES NEW DATA SUPPORTING THE POTENTIAL USE OF REMLARSEN TO PREVENT CORNEAL FIBROSIS AT THE 2019 ARVO MEETING BOULDER, CO, April 29, 2019 miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and
Read more →VRDNMIRAGEN ANNOUNCES NEW CLINICAL DATA FOR COBOMARSEN IN ATLL PATIENTS AT THE 19TH ANNUAL HTLV CONGRESS IN LIMA, PERU Continued evidence of disease stabilization observed in ATLL patients treated with cobomarsen for up to 1
MIRAGEN ANNOUNCES NEW CLINICAL DATA FOR COBOMARSEN IN ATLL PATIENTS AT THE 19TH ANNUAL HTLV CONGRESS IN LIMA, PERU BOULDER, CO, April 26, 2019 - miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RN
Read more →VRDNMIRAGEN ANNOUNCE S FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND PROVIDES 2019 OUTLOOK Cobomarsen tested in clinical trials for three different types of blood cancers Multiple clinical sites open and actively r
MIRAGEN ANNOUNCES FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND PROVIDES 2019 OUTLOOK Cobomarsen tested in clinical trials for three different types of blood cancers Multiple clinical sites open and actively recruiting in the global Phase 2 SOLAR clinical trial of cob
Read more →VRDNMIRAGEN THERAPEUTICS TO PRESENT NEW COBOMARSEN CLINICAL TRIAL DATA FOR ADULT T-CELL LEUKEMIA/LYMPHOMA AND CUTANEOUS T-CELL LYMPHOMA AT THE 11 TH ANNUAL T-CELL
MIRAGEN THERAPEUTICS TO PRESENT NEW COBOMARSEN CLINICAL TRIAL DATA FOR ADULT T-CELL LEUKEMIA/LYMPHOMA AND CUTANEOUS T-CELL LYMPHOMA AT THE 11TH ANNUAL T-CELL BOULDER, CO, December 20, 2018 - miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company f
Read more →VRDNMIRAGEN THERAPEUTICS ANNOUNCES FINAL SAFETY, BIODISTRIBUTION AND CLINICAL EFFICACY DATA FROM PHASE 1
MIRAGEN THERAPEUTICS ANNOUNCES FINAL SAFETY, BIODISTRIBUTION AND CLINICAL EFFICACY DATA FROM PHASE 1 COBOMARSEN CLINICAL TRIAL IN PATIENTS WITH MYCOSIS FUNGOIDES BOULDER, CO, December 2, 2018 miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company
Read more →VRDNMIRAGEN THERAPEUTICS ANNOUNCES THE PRESENTATION OF DATA FROM PRECLINICAL STUDIES DEMONSTRATING THE POTENTIAL ANTI-FIBROTIC EFFECT OF REMLARSEN IN THE CORNEA AT THE 2018 OLIGO MEETING IN SEATTLE, WA Remlarsen treatment in
MIRAGEN THERAPEUTICS ANNOUNCES THE PRESENTATION OF DATA FROM PRECLINICAL STUDIES DEMONSTRATING THE POTENTIAL ANTI-FIBROTIC EFFECT OF REMLARSEN IN THE CORNEA AT THE 2018 OLIGO MEETING IN SEATTLE, WA BOULDER, CO, October 1, 2018 miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clini
Read more →VRDNMIRAGEN THERAPEUTICS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE Cobomarsen expansion indication data released; first observations from the ongoing Phase 1 clinical trial on safety and eff
MIRAGEN THERAPEUTICS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE BOULDER, CO, AUGUST 7, 2018 - miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapie
Read more →VRDNMIRAGEN THERAPEUTICS AND THE LEUKEMIA & LYMPHOMA SOCIETY ENTER INTO AN AGREEMENT TO FACILITATE THE DEVELOPMENT OF COBOMARSEN IN CUTANEOUS T-CELL LYMPHOMA BOULDER, Colo. and Rye Brook, NY
MIRAGEN THERAPEUTICS AND THE LEUKEMIA & LYMPHOMA SOCIETY ENTER INTO AN AGREEMENT TO FACILITATE THE DEVELOPMENT OF COBOMARSEN IN CUTANEOUS T-CELL LYMPHOMA BOULDER, Colo. and Rye Brook, NY, August 6, 2018 miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceut
Read more →VRDNMIRAGEN THERAPEUTICS ANNOUNCES INITIATION OF PHASE 2 CLINICAL TRIAL OF MRG-201
MIRAGEN THERAPEUTICS ANNOUNCES INITIATION OF PHASE 2 CLINICAL TRIAL OF BOULDER, Colo., July 10, 2018 (GLOBE NEWSWIRE) miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today
Read more →VRDNMIRAGEN THERAPEUTICS TO PRESENT FIRST COBOMARSEN PHASE 1 CLINICAL TRIAL DATA FROM PATIENTS WITH ADULT T-CELL LEUKEMIA/LYMPHOMA AND NEW INTERIM DATA FROM PATIENTS WITH MYCOSIS FUNGOIDES AT THE 2018 AMERICAN SOCIETY OF CLI
MIRAGEN THERAPEUTICS TO PRESENT FIRST COBOMARSEN PHASE 1 CLINICAL TRIAL DATA FROM PATIENTS WITH ADULT T-CELL LEUKEMIA/LYMPHOMA AND NEW INTERIM DATA FROM PATIENTS WITH MYCOSIS FUNGOIDES AT THE 2018 AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING BOULDER, Colo., June 4, 20
Read more →VRDNMIRAGEN THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE MRG-110 advanced into clinical development with the initiation of two Phase 1 clinical trials in collaboration with Servier
MIRAGEN THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BOULDER, CO, May 9, 2018 (GLOBE NEWSWIRE) miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, tod
Read more →VRDNMIRAGEN THERAPEUTICS ANNOUNCES NEW INTERIM DATA FROM PHASE 1 CLINICAL TRIAL OF COBOMARSEN IN MYCOSIS FUNGOIDES Treatment resulted in durable improved quality of life Cobomarsen continued to be generally well tolerated at
MIRAGEN THERAPEUTICS ANNOUNCES NEW INTERIM DATA FROM PHASE 1 CLINICAL TRIAL OF COBOMARSEN IN MYCOSIS BOULDER, Colo., May 8, 2018 (GLOBE NEWSWIRE) miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RN
Read more →VRDNmiRagen Therapeutics Announces Initiation of Second Phase 1 Clinical Trial of MRG-110
miRagen Therapeutics Announces Initiation of Second Phase 1 Clinical Trial of MRG-110 BOULDER, Colo., May 1, 2018 (GLOBE NEWSWIRE) miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted ther
Read more →VRDNmiRagen Therapeutics Announces New Data Showing Administration of MRG-110 Improved Tissue Perfusion and Wound Healing in Late Stage Preclinical Studies MRG-110 appeared to increase vascularization and reparative tissue f
miRagen Therapeutics Announces New Data Showing Administration of MRG-110 Improved Tissue Perfusion and Wound Healing in Late Stage Preclinical Studies April 27, 2018 (GLOBE NEWSWIRE) miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused
Read more →VRDNMIRAGEN ANNOUNCES INITIATION OF PHASE 1 CLINICAL TRIAL OF MRG-110
MIRAGEN ANNOUNCES INITIATION OF PHASE 1 CLINICAL TRIAL OF MRG-110 BOULDER, Colo., Mar. 27, 2018 (GLOBE NEWSWIRE) miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced t
Read more →VRDNMIRAGEN THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE Data from Phase 1 clinical trial supports advancing cobomarsen, or MRG-106, into a Phase 2 potentially regist
MIRAGEN THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE BOULDER, CO, March 14, 2018 (GLOBE NEWSWIRE) miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of
Read more →VRDNMIRAGEN THERAPEUTICS
MIRAGEN THERAPEUTICS, INC. PRICES PUBLIC OFFERING OF COMMON STOCK BOULDER, Colo., Feb. 8, 2018 (GLOBE NEWSWIRE) miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announ
Read more →VRDNMIRAGEN THERAPEUTICS PRESENTS NEW DATA FROM PHASE 1 CLINICAL TRIAL OF MRG-106 IN MYCOSIS FUNGOIDES AT THE T-CELL LYMPHOMA FORUM 90% of evaluable patients show clinical improvement in the ongoing Phase 1 clinical trial of
MIRAGEN THERAPEUTICS PRESENTS NEW DATA FROM PHASE 1 CLINICAL TRIAL OF IN MYCOSIS FUNGOIDES AT THE T-CELL LYMPHOMA BOULDER, Colo., Feb. 2, 2018 (GLOBE NEWSWIRE) miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and de
Read more →VRDNMIRAGEN THERAPEUTICS PRESENTS NEW INTERIM CLINICAL DATA EXPANDING ON PREVIOUS DATA SUGGESTING POSITIVE IMPACT FROM SYSTEMICALLY ADMINISTERED MRG-106 ON MYCOSIS FUNGOIDES FORM OF CUTANEOUS T-CELL LYMPHOMA AT 2017 AMERICAN
MIRAGEN THERAPEUTICS PRESENTS NEW INTERIM CLINICAL DATA EXPANDING ON PREVIOUS DATA SUGGESTING POSITIVE IMPACT FROM SYSTEMICALLY ADMINISTERED MRG-106 ON MYCOSIS FUNGOIDES FORM OF CUTANEOUS T-CELL LYMPHOMA AT 2017 AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING BOULDER, Colo., Dec.
Read more →VRDNMIRAGEN THERAPEUTICS REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE MRG-106 Phase 1 trial expanded to include additional oncology indications, enrollment commenced MRG-201 expected to advance
MIRAGEN THERAPEUTICS REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE BOULDER, CO, November 8, 2017 (GLOBE NEWSWIRE) miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-t
Read more →VRDNMIRAGEN THERAPEUTICS PRESENTS NEW CLINICAL DATA SUGGESTING POSITIVE IMPACT FROM SYSTEMICALLY ADMINISTERED MRG-106 ON MYCOSIS FUNGOIDES FORM OF CUTANEOUS T-CELL LYMPHOMA AT EORTC GLOBAL TASK FORCE MEETING Improvements in
MIRAGEN THERAPEUTICS PRESENTS NEW CLINICAL DATA SUGGESTING POSITIVE IMPACT FROM SYSTEMICALLY ADMINISTERED MRG-106 ON MYCOSIS FUNGOIDES FORM OF CUTANEOUS T-CELL LYMPHOMA AT EORTC GLOBAL TASK FORCE MEETING BOULDER, CO, October 13, 2017 (GLOBE NEWSWIRE) miRagen Therapeutics, Inc.
Read more →VRDNMIRAGEN THERAPEUTICS PRESENTS NEW MRG-201 PRECLINICAL DATA FOR INHALED MICRORNA-29 MIMIC TARGETING PULMONARY FIBROSIS MRG-201 was nebulized and delivered to the lungs via inhalation in rodents Administration of aerosoliz
MIRAGEN THERAPEUTICS PRESENTS NEW MRG-201 PRECLINICAL DATA FOR INHALED MICRORNA-29 MIMIC TARGETING PULMONARY FIBROSIS BOULDER, CO, September 11, 2017 (GLOBE NEWSWIRE) miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery
Read more →VRDNMIRAGEN THERAPEUTICS REPORTS SECOND QUARTER 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE New MRG-106 Phase 1 cutaneous T-cell lymphoma clinical trial data released Expansion of the MRG-106 trial to include additi
MIRAGEN THERAPEUTICS REPORTS SECOND QUARTER 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE BOULDER, CO, August 11, 2017 (GLOBE NEWSWIRE) miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-t
Read more →VRDNmiRagen Therapeutics to Present MRG-106 Phase 1 Clinical Trial Data at the International Conference on Malignant Lymphoma Expanded Corporate Milestones for Coming 18 Months BOULDER, CO
miRagen Therapeutics to Present MRG-106 Phase 1 Clinical Trial at the International Conference on Malignant Lymphoma Expanded Corporate Milestones for Coming 18 Months BOULDER, CO, June 8, 2017 miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical compa
Read more →VRDNmiRagen Therapeutics Presents New Data from Phase 1 Clinical Trial Evaluating MRG-106 in Subjects with Mycosis Fungoides MRG-106 has been generally well-tolerated; Improvements in disease severity demonstrated and genera
miRagen Therapeutics Presents New Data from Phase 1 Clinical Trial Evaluating MRG-106 in Subjects with Mycosis Fungoides MRG-106 has been generally well-tolerated; Improvements in disease severity demonstrated and generally sustained through duration of therapy BOULDER, CO, J
Read more →VRDNmiRagen Therapeutics Receives EU Orphan Medicinal Product Designation for MRG-106 for the Treatment of Cutaneous T-cell Lymphoma BOULDER, CO
miRagen Therapeutics Receives EU Orphan Medicinal Product Designation for MRG-106 for the Treatment of Cutaneous T-cell Lymphoma BOULDER, CO, May 24, 2017 (GLOBE NEWSWIRE) miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the disc
Read more →VRDNmiRagen Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update MRG-106 granted orphan-drug status for the treatment of mycosis fungoides by U.S. Food and Drug Administration (FDA) miRagen
miRagen Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update BOULDER, CO, May 10, 2017 (GLOBE NEWSWIRE) Miragen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of microRNA-
Read more →VRDNServier and miRagen extend collaboration for the research, development and commercialization of microRNA-targeting therapeutics A new program targeting microRNA-92 for the treatment of cardiovascular disease and certain
Servier and miRagen extend collaboration for the research, development and commercialization of microRNA-targeting therapeutics A new program targeting microRNA-92 for the treatment of cardiovascular disease and certain other vascular flow related diseases may support regene
Read more →VRDNmiRagen Therapeutics Provides Corporate Update BOULDER, CO
miRagen Therapeutics Provides Corporate Update BOULDER, CO March 31, 2017 miRagen Therapeutics, Inc. (Nasdaq: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of microRNA-targeted therapies, today reported recent clinical and financial
Read more →VRDNmiRagen Therapeutics Completes Merger with Signal Genetics and Concurrent $40.7 Million Equity Financing Merger creates a clinical-stage biopharmaceutical company focused on the discovery and development of select microR
miRagen Therapeutics Completes Merger with Signal Genetics and Concurrent $40.7 Million Equity Financing Merger creates a clinical-stage biopharmaceutical company focused on the discovery and development of select microRNA-targeted therapies Combined company, renamed Miragen
Read more →VRDNSignal Announces Results of Special Meeting Carlsbad, CA
Signal Announces Results of Special Meeting Carlsbad, CA February 10, 2017 Signal Genetics, Inc. (Signal) (Nasdaq: SGNL) announced today that, based upon the final vote count certified by the independent inspector of elections for the special meeting of stockholders held Februa
Read more →VRDNSignal Genetics Sets Date for Special Meeting of Stockholders CARLSBAD, California (
Signal Genetics Sets Date for Special Meeting of Stockholders CARLSBAD, California (January 9, 2017) Signal Genetics, Inc. (NASDAQ: SGNL) announced today it has set a date for a special meeting of its stockholders to vote on matters related to the proposed merger with Miragen T
Read more →VRDNmiRagen Therapeutics Expands Executive Leadership Team --------------------- Paul Rubin, M.D. Joins as Executive Vice President of Research and Development BOULDER, CO.
miRagen Therapeutics Expands Executive Leadership Team --------------------- Paul Rubin, M.D. Joins as Executive Vice President of Research and Development BOULDER, CO., November 29, 2016 miRagen Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the di
Read more →VRDNSignal Genetics Regains Compliance with NASDAQ Minimum Bid Price Listing Requirement CARLSBAD, California (
Signal Genetics Regains Compliance with NASDAQ Minimum Bid Price Listing Requirement CARLSBAD, California (November 28, 2016) Signal Genetics, Inc. (NASDAQ: SGNL), a commercial stage, molecular genetics diagnostic company focused on providing innovative diagnostic services that
Read more →VRDNmiRagen Therapeutics Announces Presentation of MRG-106 Clinical Data at American Society of Hematology Annual Meeting - Initial data on MRG-106 dosing in patients with cutaneous T-cell lymphoma shows preliminary clinical
miRagen Therapeutics Announces Presentation of MRG-106 Clinical Data at American Society of Hematology Annual Meeting - Initial data on MRG-106 dosing in patients with cutaneous T-cell lymphoma shows preliminary clinical responses - BOULDER, CO miRagen Therapeutics, Inc. today
Read more →VRDNSignal Genetics and miRagen Therapeutics Investor Conference Call
Signal Genetics and miRagen Therapeutics Investor Conference Call Signal Genetics and miRagen Therapeutics Investor Conference Call, November 1, 2016 CORPORATE PARTICIPANTS Samuel D. Riccitelli, President and Chief Executive Officer, Signal Genetics William S. Marshall, Chie
Read more →VRDNmiRagen Therapeutics and Signal Genetics Sign Merger Agreement -Merger to create clinical-stage, NASDAQ-listed, biopharmaceutical company developing proprietary micro RNA-targeted therapeutics - -Concurrent financing of
miRagen Therapeutics and Signal Genetics Sign Merger Agreement -Merger to create clinical-stage, NASDAQ-listed, biopharmaceutical company developing proprietary micro RNA-targeted therapeutics - -Concurrent financing of $40 million from Miragen investor syndicate- -Combined c
Read more →Competitive Position
How VRDN ranks across every disease it competes inCompetitive Position is a premium feature
See how VRDN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial